Vedanta Biosciences, founded in 2017, is a clinical-stage company that has developed immunotherapies designed to treat immune-mediated and infectious diseases. The company's immunotherapies include a suite of proprietary assays that seek to enable physicians to access live bacteria drugs that are designed to treat autoimmune and inflammatory diseases easily. Vedanta Biosciences is headquartered in Cambridge, Massachusetts.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
07/21/2021 | Series D | $68.41MM | $xx.xx | $435.43MM | Fosun Health Capital, Health For Life Capital, Jsr Corporation, Magnetar Capital, Puretech Health, Rock Springs Capital, Shumway Capital, Skyviews Life Sciences, Symbiosis Llc, Verition Fund Manaement | |
Price per Share
$xx.xx
Shares Outstanding
2,387,676
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Fosun Health Capital, Health For Life Capital, Jsr Corporation, Magnetar Capital, Puretech Health, Rock Springs Capital, Shumway Capital, Skyviews Life Sciences, Symbiosis Llc, Verition Fund Manaement
|
||||||
01/12/2021 | Series C-2 | $41.57MM | $xx.xx | $293.79MM | Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Fc Capital, Health For Life, Invesco Asset Management, Jsr Corporation, Partners Investment Company, Pfizer, Puretech Health, Quad Investment Management, Rock Springs Capital, Shinhan Capital-Yeollim Partners, Shinhan Investment-Private Equity, Shumway Capital, Sv Investment Corp, Symbiosis | |
Price per Share
$xx.xx
Shares Outstanding
1,785,655
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Fc Capital, Health For Life, Invesco Asset Management, Jsr Corporation, Partners Investment Company, Pfizer, Puretech Health, Quad Investment Management, Rock Springs Capital, Shinhan Capital-Yeollim Partners, Shinhan Investment-Private Equity, Shumway Capital, Sv Investment Corp, Symbiosis
|
||||||
05/13/2019 | Series C | $45.39MM | $xx.xx | $235.28MM | Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Health For Life Capital, Invesco Asset Management, Jsr Corporation, Partners Investment Company, Puretech Health, Rock Springs Capital, Shumway Capital, Symbiosis Llc | |
Price per Share
$xx.xx
Shares Outstanding
2,004,173
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Bill & Melinda Gates Foundation, Bristol-Myers Squibb, Health For Life Capital, Invesco Asset Management, Jsr Corporation, Partners Investment Company, Puretech Health, Rock Springs Capital, Shumway Capital, Symbiosis Llc
|
||||||
12/21/2018 | Series B | $52.23MM | $xx.xx | $190.44MM | Undisclosed Investors | |
Price per Share
$xx.xx
Shares Outstanding
2,305,948
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
|
||||||
11/03/2017 | Series A-1 | $4MM | $xx.xx | $6.15MM | Carb-X | |
Price per Share
$xx.xx
Shares Outstanding
4,000,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
0.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Carb-X
|